SILK - Silk Road Medical Inc Stock Price, Fair Value and News

$27.49

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SILK RSI Chart

SILK Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-19.76

Price/Sales (Trailing)

5.83

Price/Free Cashflow

-30.95

SILK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SILK Fundamentals

SILK Revenue

Revenue (TTM)

191.4M

Rev. Growth (Yr)

13.12%

Rev. Growth (Qtr)

5.69%

SILK Earnings

Earnings (TTM)

-56.5M

Earnings Growth (Yr)

-23.13%

Earnings Growth (Qtr)

-17.45%

SILK Price Action

Last 7 days

0.0%

Last 30 days

1.2%

Last 90 days

1.9%

Trailing 12 Months

75.3%

SILK Profitability

Return on Equity

-36.55%

Return on Assets

-20.95%

Free Cashflow Yield

-3.23%

SILK Financial Health

Current Ratio

7.63

Debt/Equity

0.49

Debt/Cashflow

-0.45

SILK Investor Care

Shares Dilution (1Y)

4.63%

Diluted EPS (TTM)

-1.44

SILK Alerts

Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	185.5M	191.4M	0	0
2023	150.7M	162.9M	169.9M	177.1M
2022	107.4M	114.2M	126.8M	138.6M
2021	78.3M	89.7M	94.3M	101.5M
2020	69.5M	69.7M	72.7M	75.2M
2019	41.6M	48.8M	56.2M	63.4M
2018	19.3M	24.4M	29.5M	34.6M
2017	0	0	0	14.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Silk Road Medical Inc

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure. Silk Road Medical, Inc. was incorporated in 2007 and is headquartered in Sunnyvale, California.

CEO	Ms. Erica J. Rogers
WEBSITE	https://silkroadmed.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	414

Silk Road Medical Inc Frequently Asked Questions

What is the ticker symbol for Silk Road Medical Inc? What does SILK stand for in stocks?

SILK is the stock ticker symbol of Silk Road Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silk Road Medical Inc (SILK)?

As of Thu Sep 26 2024, market cap of Silk Road Medical Inc is 1.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SILK stock?

You can check SILK's fair value in chart for subscribers.

Is Silk Road Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SILK is over valued or under valued. Whether Silk Road Medical Inc is cheap or expensive depends on the assumptions which impact Silk Road Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SILK.

What is Silk Road Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Sep 26 2024, SILK's PE ratio (Price to Earnings) is -19.76 and Price to Sales (PS) ratio is 5.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SILK PE ratio will change depending on the future growth rate expectations of investors.